Semler Scientific, Inc.
Semler Scientific, Inc. (SMLR) Financial Performance & Income Statement Overview
Review Semler Scientific, Inc. (SMLR) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Semler Scientific, Inc. (SMLR) Income Statement & Financial Overview
Analyze Semler Scientific, Inc.’s SMLR earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $8.84M | $12.41M | $13.51M | $14.46M |
| Cost of Revenue | $937000.00 | $1.10M | $1.16M | $1.25M |
| Gross Profit | $7.90M | $11.31M | $12.36M | $13.21M |
| Gross Profit Ratio | $0.89 | $0.91 | $0.91 | $0.91 |
| R&D Expenses | $1.31M | $1.03M | $1.19M | $1.44M |
| SG&A Expenses | $7.93M | $6.74M | $6.11M | $6.42M |
| Operating Expenses | $39.00M | $7.77M | $7.29M | $7.86M |
| Total Costs & Expenses | $39.94M | $8.87M | $8.45M | $9.12M |
| Interest Income | $0.00 | $178000.00 | $168000.00 | $714000.00 |
| Interest Expense | -$943000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $99000.00 | $143000.00 | $195000.00 |
| EBITDA | -$31.10M | $3.64M | $6.52M | $5.35M |
| EBITDA Ratio | -$3.52 | $0.29 | $0.48 | $0.37 |
| Operating Income | -$31.10M | $3.54M | $5.07M | $5.35M |
| Operating Income Ratio | -$3.52 | $0.29 | $0.37 | $0.37 |
| Other Income/Expenses (Net) | -$43.77M | $29.03M | $1.31M | -$4.21M |
| Income Before Tax | -$74.87M | $32.58M | $6.38M | $1.14M |
| Income Before Tax Ratio | -$8.47 | $2.62 | $0.47 | $0.08 |
| Income Tax Expense | -$10.17M | $3.37M | $766000.00 | $1.13M |
| Net Income | -$64.70M | $29.21M | $5.61M | $11000.00 |
| Net Income Ratio | -$7.32 | $2.35 | $0.42 | $0.001 |
| EPS | -$6.74 | $3.64 | $0.80 | $0.002 |
| Diluted EPS | -$6.74 | $3.41 | $0.72 | $0.001 |
| Weighted Avg Shares Outstanding | $9.60M | $7.23M | $7.05M | $6.94M |
| Weighted Avg Shares Outstanding (Diluted) | $9.60M | $7.98M | $7.77M | $7.80M |
Financial performance has remained strong, with revenue growing from $14.46M in Q2 2024 to $8.84M in Q1 2025. Gross profit continued to perform well, with margins at 89% in the latest quarter. Operating income reached -$31.10M in Q1 2025, holding a steady -352% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$31.10M. Net income dropped to -$64.70M, keeping EPS at -$6.74. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan